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Epoxy-tiglianes are a novel class of diterpene esters.  The prototype epoxy-tigliane, EBC-46 
(tigilanol tiglate), possesses potent anti-cancer properties and is currently in clinical 
development as a local treatment for human and veterinary cutaneous tumors.  EBC-46 rapidly 
destroys treated tumors and consistently promotes wound re-epithelialization at sites of tumor 
destruction.  However, the mechanisms underlying these keratinocyte wound healing responses 
are not completely understood.  Here, we investigated the effects of EBC-46 and an analogue 
(EBC-211) at 1.51 nM-151 µM concentrations, on wound healing responses in immortalized 
human skin keratinocytes (HaCaTs).  Both EBC-46 and EBC-211 (1.51 nM-15.1 µM) 
accelerated G0/G1-S and S-G2/M cell cycle transitions and HaCaT proliferation.  EBC-46 
(1.51-151 nM) and EBC-211 (1.51 nM-15.1 µM) further induced significant HaCaT migration 
and scratch wound repopulation.  Stimulated migration/wound repopulation responses were 
even induced by EBC-46 (1.51 nM) and EBC-211 (1.51-151 nM) with proliferation inhibitor, 
mitomycin C (1 μM), suggesting that epoxy-tiglianes can promote migration and wound 
repopulation independently of proliferation.  Expression profiling analyses showed that epoxy-
tiglianes modulated keratin, DNA synthesis/replication, cell cycle/proliferation, 
motility/migration, differentiation, matrix metalloproteinase (MMP) and cytokine/chemokine 
gene expression, to facilitate enhanced responses.  Although epoxy-tiglianes down-regulated 
established cytokine and chemokine agonists of keratinocyte proliferation and migration, 
enhanced HaCaT responses were demonstrated to be mediated via protein kinase C (PKC) 
phosphorylation and significantly abrogated by pan-PKC inhibitor, bisindolylmaleimide-1 
(BIM-1, 1 μM).  By identifying how epoxy-tiglianes stimulate keratinocyte healing responses 
and re-epithelialization in treated skin, our findings support the further development of this 
class of small molecules as potential therapeutics for other clinical situations associated with 
impaired re-epithelialization, such as non-healing skin wounds. 
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Epoxy-tiglianes are a novel class of diterpene esters isolated from a native Australian rainforest 
plant, Fontainea picrosperma (Euphorbiaceae).  The prototype epoxy-tigliane, EBC-46 (12-
tigloyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one, now 
known as tigilanol tiglate), possesses potent anti-cancer properties in pre-clinical syngeneic and 
xenograft mouse models [1,2]; and is currently under clinical evaluation as a treatment for 
cutaneous and subcutaneous tumors in humans and domesticated animals [2,3], having recently 
completed a Phase I/II human dose escalation safety trial [4].  Following intra-tumoral 
administration, EBC-46 elicits a rapid, but localized, inflammatory response and loss of 
integrity of the tumor vasculature, leading to hemorrhagic necrosis and subsequent tumor 
ablation in melanoma, squamous cell carcinoma and other tumor mouse models; mediated at 
least in part via protein kinase C (PKC) activation [1].  Remarkably, EBC-46 also stimulates 
exceptional dermal wound healing in vivo following tumor destruction, particularly manifested 
as accelerated wound re-epithelialization and closure over a 1-month period post-treatment [2-
3].  However, little is currently known how epoxy-tiglianes induce such favorable epithelial 
wound healing outcomes. 
 Wound re-epithelialization is an essential process during normal healing, facilitating 
wound closure and the restoration of skin barrier function through the re-establishment of the 
denuded epithelium by epidermal keratinocytes [5,6].  However, intrinsic differences in the 
functionality of wound keratinocytes, such as the hyper-proliferative nature of supra-basal 
keratinocytes, their hyper-adhesive/non-migratory phenotypes and dysregulated 
differentiation/regulatory pathways [7-11]; lead to impaired re-epithelialization and a failure to 
reinstate barrier integrity.  Such events culminate in clinical problems, such as non-healing 
chronic skin wounds [12,13].  Despite many modalities being available for the treatment or 
management of chronic wounds, these often offer limited benefit to healing outcomes and 
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consequently, non-healing or wound recurrence remain common [14,15].  Current 
pharmaceutical-based therapies are also severely limited, as Regranex® (Becaplermin) is the 
only FDA (US Food and Drug Administration)-approved pharmaceutical for chronic skin 
wounds.  However, in addition to being restricted for the treatment of diabetic wounds only, 
significant efficacy and safety issues surround its use [16].  Consequently, there is a significant 
unmet clinical need for novel and more efficacious pharmaceuticals capable of restoring re-
epithelialization and healing in chronic skin wounds [17]. 
 Therefore, in this study, we investigated how epoxy-tiglianes, EBC-46 and an EBC-46 
analogue, EBC-211 (produced by a Payne re-arrangement of the epoxide group on the β ring of 
EBC-46, circled in red, Fig. 1A), modulate such wound healing responses in HaCaT human 
immortalized keratinocytes, in line with the enhanced wound re-epithelialization clinically 
observed in vivo.  Our results demonstrate that both epoxy-tiglianes exert significant 
stimulatory effects on keratinocyte wound healing responses, facilitated via PKC activation and 
the downstream manipulation of gene expression profiles in favor of enhanced proliferation and 
migration.  Such findings demonstrate the mechanisms by which epoxy-tiglianes mediate 
wound re-epithelialization, closure and restoration of skin barrier function following tumor 
destruction.  In addition, the findings advocate the further investigation of this class of small 
molecules as novel pharmaceutical therapies for other clinical situations associated with 
impaired re-epithelialization, such as non-healing skin wounds. 
 
2. Materials and methods 
2.1. Chemicals, reagents and antibodies 
EBC-46 and EBC-211 were provided by QBiotics Group (Yungaburra, Australia).  Dulbecco’s 
modified eagle medium (DMEM), antibiotics/antimycotics, fetal calf serum (FCS), L-
glutamine, dimethyl sulfoxide (DMSO, ≥99.7%) and RIPA buffer, were purchased from 
ThermoFisher Scientific (Paisley, UK).  3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium 
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bromide (MTT), mitomycin C (MC), Tween 20 and bovine serum albumin (BSA) were 
obtained from Sigma-Aldrich (Poole, UK). Fluorescent probe, Draq5™, was purchased from 
BioStatus (Shepshed, UK).  4% Paraformaldehyde in phosphate buffered saline (PBS) was 
supplied by Santa Cruz Biotechnology (Dallas, TX, USA).  RNAprotect Cell Reagent was 
obtained from Qiagen (Manchester, UK).  ECL™ Prime Detection Reagent was purchased from 
VWR International (Lutterworth, UK).  Pan-PKC inhibitor, bisindolylmaleimide-1 (BIM-1), 
was obtained from Merck Millipore (Watford, UK).  Primary antibodies against cytokeratin 13 
(#ab133340), cytokeratin 15 (#ab52816), cytokeratin 16 (#ab76416), cytokeratin 17 
(#ab109725), KRT6B (#ab154313), cyclin A2 (#ab137769), cyclin B1 (#ab32053), cyclin B2 
(#ab185622), CDKN3 (#ab175393), p21 (CDKN1A, #ab109520), UBE2C (#ab125002), 
S100A4 (#ab124805), MRP8 (S100A8, #ab92331) and β-actin Loading Control (#ab8227) 
were purchased from Abcam (Cambridge, UK).  Phospho-PKC (pan) primary antibody (#9371) 
was purchased form Cell Signaling Technology (Danvers, MA, USA).  Horseradish peroxidase-
conjugated secondary antibody (#P039901-2) was obtained from Dako (Ely, UK).  All 
remaining reagents were of highest grade and either supplied by ThermoFisher Scientific or 
Sigma-Aldrich. 
 
2.2. Cell culture 
The immortalized human skin keratinocyte cell line (HaCaTs) was obtained from the German 
Cancer Research Centre (Heidelberg, Germany).  HaCaTs were cultured in DMEM, 
supplemented with 1% antibiotics/antimycotics (100 U/mL penicillin G sodium, 100 μg/mL 
streptomycin sulfate and 0.25 μg/mL amphotericin B), 2 mM L-glutamine and 10% FCS [18].  
HaCaTs were maintained at 37 °C in a humidified 5% CO2/95% air atmosphere, with medium 
changed every 48 h. 
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For epoxy-tigliane-containing cultures, EBC-46 and EBC-211 were initially solubilized 
in DMSO at 178 mM (100 mg/mL) and 17.8 mM (10 mg/mL), respectively.  Stock solutions 
were used to prepare further epoxy-tiglianes dilutions in DMSO, prior to dilution in 1% serum-
containing DMEM at 1.78 nM-178 µM (DMSO concentrations, ≤1%).  Total epoxy-tigliane 
solubility was subsequently confirmed by preparation of EBC-46 and EBC-211 (1.78 μM, 17.8 
μM and 178 μM) in 1% serum-containing DMEM with ≤1% DMSO, centrifugation (15,000 
rpm, 10 min) and subsequent analysis using a Shimadzu Prominence LC-20 HPLC System 
(Shimadzu, Sydney, Australia), at 249 nm, with a Halo RP-Amide 2.7 μm, 150 mm x 4.6 mm 
column (Hichrom, Lutterworth, UK); and acetonitrile/water solvent scheme.  Profiles were 
compared verses linear standard curves prepared using EBC-46 and EBC-211 in DMSO (0.001-
0.5 mg/mL, 1.78 μM-0.89 mM).  As the solubility of both epoxy-tiglianes were determined to 
be 85% in 1% serum-containing DMEM with ≤1% DMSO, final EBC-46 and EBC-211 
concentrations were adjusted to 1.51 nM-151 µM, based on a solubility factor of x0.85.  
Untreated control cultures were also supplemented with 1% DMSO, to discount influences on 
HaCaT behavior in epoxy-tigliane-treated cultures. 
 
2.3. Cell proliferation and viability assays 
HaCaTs were seeded into 96-well micro-titer plates in 10% serum-containing DMEM at 5×103 
cells/well for 24 h, followed by incubation in serum-free DMEM for another 24 h.  Serum-free 
media was replaced with 1% serum-containing DMEM with 0-151 µM EBC-46 and EBC-211 
(6 wells/epoxy-tigliane concentration).  Cultures were maintained at 37 °C in a humidified 5% 
CO2/95% air atmosphere, with medium changed every 48 h.  HaCaT proliferation and viability 
were assessed at 24 h, 72 h, 120 h and 168 h, by MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyltetrazolium bromide] assay [19].  Absorbance values were measured using a Bio-Tek 
Instruments Microplate Autoreader (ThermoFisher Scientific), at 540 nm.  Epoxy-tigliane 
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effects on cell proliferation and viability were expressed as percent viable cells versus untreated 
controls, which were arbitrarily assigned a viability of 100%. 
 
2.4. Cell cycle analysis 
HaCaTs were seeded into 6-well plates in 10% serum-containing DMEM at 7.5×104 cells/well 
for 24 h, followed by cell cycle synchronization in serum-free DMEM for another 24 h.  Serum-
free media was replaced with 1% serum-containing DMEM with 0-15.1 µM EBC-46 and EBC-
211 (3 wells/epoxy-tigliane concentration).  Cultures were maintained at 37 °C in a humidified 
5% CO2/95% air atmosphere, for 9 h, 17 h, 26 h, 32 h, 40 h and 48 h; with 0 h analyzed at time 
of epoxy-tigliane treatment.  At each time-point, cells were fixed with 4% paraformaldehyde in 
PBS and re-suspended in PBS.  Fluorescent probe, Draq5™ (20 µM) [20], was added and flow 
cytometry performed (FACSCalibur™, BD Biosciences, Oxford, UK), per manufacturer’s 
instructions.  Data analysis was performed using FlowJo Software (BD Biosciences, Ashland, 
OR, USA). 
 
2.5. Scratch wound repopulation 
HaCaTs were seeded into 24-well plates in 10% serum-containing DMEM at 7.5×104 cells/well 
for 48 h, followed by incubation in serum-free DMEM for another 24 h.  Serum-free DMEM 
was removed and scratch wounds made using sterile pipettes.  Following PBS washing (×2), 
1% serum-containing DMEM with 0-15.1 µM EBC-46 and EBC-211 (3 wells/epoxy-tigliane 
concentration) was added and cultures maintained at 37 °C in a humidified 5% CO2/95% air 
atmosphere for 48 h.  HaCaT migration and scratch wound repopulation were monitored by 
Time-Lapse Confocal Microscopy (TCS SP5 Microscope, Leica Microsystems, Milton Keynes, 
UK) [18].  Digital images were taken every 20 min over 48 h, using LAS AF Lite Software.  
Scratch wound repopulation rates were quantified using ImageJ® Software (Version 1.49, 
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https://imagej.nih.gov/ij/).  Experiments were also repeated with sub-lethal concentrations of 
anti-proliferative agent, MC (1 µM), to delineate the extent to which epoxy-tigliane induced 
proliferative responses contributed to HaCaT scratch wound repopulation.  Data were expressed 
as percentage wound closure at 24 h and 48 h, versus wound areas at 0 h. 
 
2.6. Microarray analysis 
HaCaTs were seeded into T-75 tissue culture flasks in 10% serum-containing DMEM at 2×106 
cells/flask for 24 h, followed by incubation in serum-free DMEM for another 24 h.  Serum-free 
media was replaced with 1% serum-containing DMEM with EBC-46 and EBC-211 (0 or 1.51 
nM, 151 nM and 15.1 µM).  Cultures were maintained at 37 °C in a humidified 5% CO2/95% 
air atmosphere, for 24 h or 48 h.  Culture medium was then replaced with RNAprotect Cell 
Reagent.  RNA was extracted, amplified and labelled, using RNeasy Plus Mini Kits (Qiagen, 
Chadstone, Australia) and TotalPrep RNA Amplification Kits (ThermoFisher Scientific, 
Scoresby, Australia), according to manufacturers’ instructions.  Complementary RNA samples 
were hybridized to Human HT-12 v4 Expression BeadChips for Microarray analysis, using the 
Whole-Genome Gene Expression Direct Hybridization Assay System (Illumina, San Diego, 
CA, USA), as per manufacturer’s instructions.  BeadChips were scanned using the iScan 
System and BeadScan Software (Illumina). 
Scanned data were uploaded into BeadStudio Gene Expression Module (Illumina) and 
imported into GeneSpring GX Expression Analysis Software (Agilent Technologies, Santa 
Clara, CA, USA), for normalization, filtering, statistical analysis and heatmap 
visualization/clustering.  Data from each treatment group (n=4 replicate experiments) were 
grouped for combined analysis, using Ingenuity Pathway Analysis (IPA®) Software.  Other 
databases used to identify the functional characteristics for genes of interest relevant to 
keratinocyte biology and re-epithelialization, included PubMed 
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(http://www.ncbi.nlm.nih.gov/pubmed) and UniProt (https://www.uniprot.org/).  Microarray 
data were deposited on the Gene Expression Omnibus (GEO) database 
(http://identifiers.org/geo:GSE122297). 
 
2.7. Western blot analysis 
HaCaTs were seeded and treated with 1% serum-containing DMEM with 0-15.1 µM EBC-46 
and EBC-211, as above.  Cultures were harvested with RIPA buffer (1 mL), containing 
Complete Protease Inhibitor Cocktail Tablets (Roche, Burgess Hill, UK).  Protein samples (10 
μg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) on pre-formed 4-15% TGX™ gels (Mini-Protean® Tetra Cell System; Bio-Rad, Hemel 
Hempstead, UK).  Gels were electroblotted onto polyvinylidene difluoride (PVDF) membranes 
(Hybond™-P, ThermoFisher Scientific), except for phospho-PKC (pan) blots where 
nitrocellulose membranes (ThermoFisher Scientific) were used.  Electroblotting was performed 
using a Mini Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad), as per manufacturer’s 
instructions. 
PVDF membranes were blocked with 5% semi-skimmed milk/1% Tween 20 in Tris-
buffered saline (TBS) for 1 h at room temperature, followed by primary antibody incubation in 
5% semi-skimmed milk/1% Tween 20, for 1 h at room temperature or 4°C overnight.  
Nitrocellulose membranes were blocked with 5% BSA/1% Tween 20 in TBS for 1 h at room 
temperature, followed by primary antibody incubation in 5% BSA/1% Tween 20/TBS, for 1 h 
at room temperature or 4°C overnight.  All membranes were washed (×3) in 1% Tween 20/TBS 
and incubated with horseradish peroxidase-conjugated secondary antibody, in 5% semi-
skimmed milk/1% Tween 20/TBS for 1 h at room temperature.  Membranes were washed (×3) 
as above, followed by additional 5 min washes (×1) in TBS.  Membranes were incubated in 
ECL™ Prime Detection Reagent and autoradiographic films (Hyperfilm™-ECL, ThermoFisher 
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Scientific) developed, per manufacturer’s instructions.  Immunoblot images were captured and 
densitometric analysis performed using ImageJ® Software, with untreated controls at each 
respective time-point representing 1.0-fold. 
 
2.8. MMP activity quantification 
HaCaTs were seeded and treated with 1% serum-containing DMEM with 0-15.1 µM EBC-46 
and EBC-211, as above.  Cultures were maintained at 37 °C in a humidified 5% CO2/95% air 
atmosphere, for 24 h or 48 h.  Culture media was collected and MMP-1, MMP-7 and MMP-10 
activities quantified using SensoLyte® 520 Activity Assays (Cambridge Bioscience, 
Cambridge, UK), according to manufacturer’s instructions at 490 nm/520 nm, as above.  
Activities were expressed as relative fluorescence units (RFU). 
 
2.9. Cytokine and chemokine level quantification 
HaCaTs were seeded and treated with 1% serum-containing DMEM with 0-15.1 µM EBC-46 
and EBC-211, as above.  Cultures were maintained at 37 °C in a humidified 5% CO2/95% air 
atmosphere, for 24 h or 48 h.  Culture media was collected and epoxy-tigliane effects on IL-6, 
IL-8, CCL5 and CXCL10 levels quantified using Quantikine® ELISAs (R&D Systems, 
Abingdon, UK), as per manufacturer’s instructions.  Absorbance values were measured at 450 
nm as above, with data expressed as pg/mL. 
 
2.10. PKC involvement in epoxy-tigliane wound healing responses 
HaCaTs were seeded, as above.  HaCaTs were subsequently incubated in 1% serum-containing 
DMEM with EBC-46 and EBC-211 (0 or 1.51 nM, 151 nM and 15.1 µM) ± sub-lethal 
concentrations of pan-PKC inhibitor, BIM-1 (1 μM, solubilized in DMSO), followed by 
assessment of HaCaT proliferation at 24 h, 48 h and 72 h (MTT assay) and HaCaT 
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migration/wound repopulation at 24 h and 48 h (Time-Lapse Microscopy), as above.  PKC 
effects on keratin (KRT17) and cell cycle/proliferation-associated (cyclin B1, CDKN1A) 
protein levels, with EBC-46 and EBC-211 (1.51 nM, 151 nM and 15.1 µM), were confirmed 
by Western blot analysis (10 μg protein samples) as above, ± BIM-1 (1 μM).  PKC effects on 
MMP-1, MMP-7 and MMP-10 activities with EBC-46 and EBC-211 (1.51 nM, 151 nM and 
15.1 µM), were confirmed by activity assays as above, ± BIM-1 (1 μM). 
To confirm PKC phosphorylation and activation following epoxy-tigliane treatment, 
HaCaTs were seeded into T-75 tissue culture flasks and treated with EBC-46 and EBC-211 (0 
or 1.51 nM, 151 nM and 15.1 µM) for 0 h, 30 min, 1 h, 3 h, 6 h and 24 h.  Cell extracts were 
harvested and protein samples (10 μg) separated and electroblotted, as above.  Membranes were 
blocked in 5% BSA/1% Tween 20 in TBS and immuno-probed with phospho-PKC (pan) 
primary antibody in 5% BSA/1% Tween 20/TBS, at 4°C overnight.  Protein loading 
confirmation, secondary antibody incubations, protein detection and image capture, were 
performed as above. 
 
2.11. Statistical analysis 
Microarrays were performed on n=4 replicate experiments.  All other experiments were 
performed on n=3 independent occasions.  Data were expressed as mean ± standard error of the 
mean (SEM).  Proliferation, wound repopulation, MMP activity and ELISA data were analyzed 
by one-way ANOVA with post-Tukey test.  Cell cycle data were analyzed using one-way 
ANOVA with Dunnett Multiple Comparisons test.  Western blot densitometry data were 
analyzed using unpaired Student’s t tests.  Microarray data were analyzed using unpaired 
Student’s t tests, with Benjamini/Hochberg multiple test correction.  Significance were 
considered at p<0.05.  Tables summarizing the statistically significant differences identified in 
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each experiment following epoxy-tigliane treatment versus untreated controls; are accessible 
via the Supplementary Dataset [21]. 
 
3. Results 
3.1. Epoxy-tiglianes stimulate keratinocyte cell cycle progression and proliferation 
Initial studies determined whether EBC-46 and EBC-211 (1.51 nM-151 µM) stimulated HaCaT 
proliferation in vitro versus untreated controls, by MTT assay.  Although both epoxy-tiglianes 
induced significant cytotoxicity at 151 µM (p<0.001 at all time-points), stimulated proliferative 
responses were evident with 1.51 nM-15.1 µM EBC-46 and EBC-211 (Fig. 1B & C).  Most 
profound proliferation effects were observed at 72 h across all epoxy-tigliane concentrations 
(p<0.001).  Enhanced proliferative responses were also apparent at 24 h (1.51 nM, p<0.01), 120 
h (1.51 nM and 1.51 µM EBC-46; 1.51-151 nM EBC-211, p<0.001); and 168 h (1.51 nM and 
151 nM-15.1 µM EBC-46; 1.51 nM-151 µM EBC-211, p<0.001-0.05). 
 Based on these stimulated HaCaT proliferative responses, flow cytometry confirmed 
epoxy-tigliane effects on HaCaT cell cycle progression.  Following cell cycle synchronization 
by serum starvation (0 h), no significant differences were identified between EBC-46-treated 
and untreated controls at 9 h (p>0.05, [21]).  However, at 17 h, 26 h, 32 h and 40 h, significant 
cycle progression through G0/G1-S and S-G2/M phases was evident versus controls at all EBC-
46 concentrations (p<0.01-0.05, Fig. 1D at 40 h and at 17 h, 26 h and 32 h, [21]), corroborating 
significantly increased proliferative responses between 24-72 h (Fig. 1B).  Only marginal 
increases in cell cycle progression were evident at 48 h (p<0.05, [21]).  EBC-211-treated 
HaCaTs demonstrated similarly increased cell cycle progression versus untreated controls, 
albeit with less dramatic cell cycle acceleration than EBC-46.  Although no significant 
differences were observed at 0 h, 9 h or 17 h (p>0.05, [21]), significant cell cycle progression 
through G0/G1-S and S-G2/M phases was evident at 26 h, 32 h, 40 h and 48 h versus controls, 
at all EBC-211 concentrations (p<0.01-0.05, Fig. 1E at 40 h and 26 h, 32 h and 48 h, [21]). 
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3.2. Epoxy-tiglianes stimulate keratinocyte scratch wound repopulation 
We next assessed EBC-46 and EBC-211 (1.51 nM-15.1 µM) effects on HaCaT migration and 
wound repopulation using automated in vitro scratch wounds.  Time-Lapse images and ImageJ® 
analysis showed HaCaT migration and re-population of denuded wound spaces, with untreated 
controls promoting ≈50% closure over 48 h (Fig. 2A & B and 2C & D for EBC-46 and EBC-
211, respectively).  Although wound closure was not significantly different with most EBC-46-
treated HaCaTs (15.1 nM-15.1 µM) versus controls at 24 h (p>0.05, Fig. 2A & B and 
Supplementary Video S1 online), 1.51 nM EBC-46 did significantly enhance closure at 24 h 
(p<0.01, Fig. 2A & B and Supplementary Video S2 online).  At 48 h, significantly increased 
closure was further evident at 1.51-151 nM EBC-46 versus controls (p<0.001-0.01), with 
almost complete closure observed due to enhanced wound edge HaCaT migration and increased 
bursts of proliferation behind the migrating front between 24-48 h (Fig. 2A & B and 
Supplementary Videos S1 & S2 online for untreated and 1.51 nM EBC-46 treated HaCaTs 
respectively; Supplementary Videos for 15.1-151 nM EBC-46 treated HaCaTs, [21]).  
However, higher EBC-46 concentrations (1.51-15.1 µM) demonstrated no significant 
differences in wound closure rates (p>0.05, Fig. 2A & B and Supplementary Videos [21]). 
Similar responses were evident with EBC-211 over a wider concentration range (Fig. 
2C & D and Supplementary Videos S3 & S4 online for untreated and 1.51 nM EBC-211 treated 
HaCaTs; Supplementary Videos for 15.1 nM-15.1 µM EBC-211 treated HaCaTs, [21]), with 
increased wound edge HaCaT migration and adjacent cell proliferation resulting in significantly 
enhanced wound closure with 1.51-151 nM EBC-211 at 24 h (p<0.001-0.05) and 1.51 nM-15.1 
µM EBC-211 at 48 h (p<0.001-0.05).  This was particularly apparent at 1.51-151 nM EBC-





3.3. Epoxy-tigliane stimulation of wound repopulation independently of proliferation 
As wound repopulation is dependent on the induction of both migratory and proliferative 
responses, we next ascertained the extent to which the significantly induced proliferative 
responses in epoxy-tigliane-treated HaCaTs contributed to enhance scratch wound repopulation 
using anti-proliferative agent, MC.  Time-Lapse Microscopy and ImageJ® analysis over 48 h 
confirmed significant EBC-46 (1.51 nM-1.51 µM) stimulation of wound closure versus 
untreated controls (Fig. 3A and Supplementary Videos, [21]), even with MC.  At 24 h, only 
1.51 nM EBC-46 induced significant closure with MC versus controls, both with and without 
MC (p<0.001).  At 48 h, significantly enhanced closure was further evident with 1.51 nM-1.51 
µM EBC-46 and MC (p<0.001-0.05), compared to controls with and without MC (Fig. 3A and 
Supplementary Videos, [21]).  Similar findings were obtained with EBC-211, with increased 
wound closure following treatment with 1.51 nM-1.51 µM EBC-211 and MC, versus controls 
with and without MC (Fig. 3B and Supplementary Videos, [21]).  Wound closure was 
significantly increased with 1.51-151 nM EBC-211 and MC at 24 h (p<0.001-0.01), with further 
enhancements at 48 h with 1.51 nM-1.51 µM EBC-211 and MC (p<0.001), compared to 
controls with and without MC. 
 
3.4. Epoxy-tiglianes alter keratinocyte gene expression profiles to stimulate proliferation and 
migration 
Having demonstrated clear epoxy-tigliane stimulatory effects on HaCaT proliferation and 
migration/wound repopulation responses, we next performed global gene expression analysis 
to explain these findings.  EBC-46 and EBC-211 (1.51 nM, 151 nM and 15.1 µM) effects on 
HaCaT gene expression were assessed at 24 h and 48 h.  Expression analysis identified 
numerous genes to be differentially expressed by EBC-46 and EBC-211 versus untreated 
controls, particularly at 48 h.  Hierarchical clustering heatmaps (Fig. 4A) demonstrated that for 
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most genes, similar expression changes were induced irrespective of epoxy-tigliane or 
concentration.  Due to the large numbers identified, only genes differentially expressed ≥2-fold 
were analysed further.  Differentially expressed genes were classified with particular relevance 
to keratinocyte wound healing responses, potentially contributing to stimulatory epoxy-tigliane 
effects on keratinocyte proliferation and migration.  These included keratin (KRT); DNA 
synthesis/replication; cell cycle, proliferation and apoptosis; adhesion/migration; 
differentiation; proteinase; and cytokine/chemokine genes (Tables presenting these 
differentially expressed gene categories are available, [21]).  See GEO database (GSE122297) 
for full dataset. 
 
3.5. Epoxy-tiglianes modulate keratin protein levels to enhance keratinocyte proliferation and 
migration 
In line with the key roles that KRTs play in keratinocyte biology and re-epithelialization [5,22], 
the significant up-regulation of KRT9, KRT13, KRT15 and down-regulation of KRT6B, 
KRT16, KRT17 by epoxy-tiglianes were particularly striking.  Concurrent with expression 
findings, Western blot validation showed limited increases in KRT13 protein levels versus 
untreated controls with EBC-46 and EBC-211 at 24 h (p>0.05, [21]), although further increases 
in KRT13 were shown at 48 h with 1.51 nM-15.1 µM EBC-46 [21] and 151 nM EBC-211 
(p<0.05, Fig. 4B).  Although no significant decrease in KRT15 detection levels were identified 
with EBC-46 (p>0.05, [21]), a significant decrease in KRT15 was evident with 15.1 µM EBC-
211 at 24 h (p<0.05, Fig. 4C), but not 48 h [21].  However, despite suggested KRT16, KRT17 
and KRT6B down-regulation by expression profiling analysis, no consistent decreases in 





3.6. Epoxy-tiglianes influence cell cycle-related proteins to enhance keratinocyte proliferation 
and migration 
A number of significantly up-regulated (cyclin A2, cyclin B1, cyclin B2, CDKN3 and UBE2C) 
and down-regulated (CDKN1A) cell cycle-related genes, were also assessed at the protein level.  
Although Western blotting demonstrated equivalent cyclin A2 detection with EBC-46 and 
EBC-211 versus untreated controls at 24 h [21], in line with the profiling findings, significantly 
increased cyclin A2 protein expression (Fig. 5A) were detectable with 15.1 nM and 1.51 µM 
EBC-46 (p<0.05), at 48h; but not with EBC-211 (p>0.05, [21]).  Cyclin B1 also exhibited 
increased levels of detectable protein expression with 151 nM-15.1 µM EBC-46 (Fig. 5B), at 
24 h only (p<0.001-0.01).  Cyclin B2 protein levels were significantly increased by EBC-46 
(Fig. 5C) at 24 h (15.1 µM, p<0.05) and 48 h (151 nM-15.1 µM, p<0.05).  Although non-
significant increases in cyclin B1 protein levels were consistently detectable with EBC-211 at 
24 h and 48 h [21], significantly increased cyclin B2 detection was apparent with 1.51 nM EBC-
211 (p<0.05), at 48 h only (Fig. 5D).  CDKN3 and UBE2C detection exhibited no discernible 
differences with EBC-46 or EBC-211 at 24 h or 48 h (p>0.05, [21]).  In contrast, cell cycle 
inhibitor, CDKN1A, showed significantly reduced levels at 24 h (Fig. 5E), following treatment 
with 1.51 nM-15.1 µM EBC-46 and EBC-211 (p<0.001), although reductions were less 
apparent at 48 h (p>0.05, [21]). 
 
3.7. Epoxy-tiglianes increase matrix metalloproteinase activities in keratinocytes 
As matrix metalloproteinases (MMPs) have prominent roles in mediating keratinocyte 
detachment from the basal lamina and migration across the wound extracellular matrix (ECM) 
[5], the epoxy-tigliane-induced up-regulation of MMP-1, MMP-7 and MMP-10 were 
noteworthy, given the absence of up-regulated MMP inhibitor expression [21] (GEO database, 
GSE122297).  Activity assays confirmed increased MMP expression following epoxy-tigliane 
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treatments (Fig. 6A), with significantly elevated MMP-1 activities with 1.51 nM-1.51 µM EBC-
211 at 24 h (p<0.001); and both epoxy-tiglianes at 48h (1.51 nM-15.1 µM, p<0.001-0.05).  
Similarly, MMP-7 activities (Fig. 6B) were significantly increased by 1.51-151 nM EBC-46 
(p<0.01-0.05) and 1.51 nM-1.51 µM EBC-211 (p<0.01-0.05) at 24 h; in addition to 1.51-15.1 
nM EBC-46 (p<0.001-0.05) and 1.51 nM-1.51 µM EBC-211 (p<0.001-0.05), at 48 h.  Although 
EBC-46 induced no significant increases in MMP-10 activities (p>0.05, Fig. 6C), significantly 
increased MMP-10 activities were shown with 1.51 nM-15.1 µM EBC-211 at 24h and 48h 
(p<0.001-0.01). 
 
3.8. Epoxy-tiglianes regulate S100 protein expression in keratinocytes 
As highlighted by the expression profiling analyses [21] (GEO database, GSE122297), 
differentially expressed S100 proteins also possess influential roles on keratinocyte 
proliferation and migration [23,24].  Western blotting demonstrated no significant differences 
in S100A4 protein levels with 1.51 nM-15.1 µM EBC-211 treatment versus untreated controls 
at 24 h or 48 h (p>0.05, [21]), although significant increases in S100A4 were detectable at 24 
h (Fig. 6D) with 15.1 µM EBC-46 (p<0.05).  Despite S100A8 being undetectable in control 
and epoxy-tigliane-treated cultures at 24 h [21], significantly decreased S100A8 protein levels 
were determined at 48 h versus untreated controls (Fig. 6E) with 1.51 nM-15.1 µM EBC-46 
(p<0.001); and with 151 nM and 15.1 µM EBC-211 (p<0.05). 
 
3.9. Epoxy-tiglianes down-regulate established cytokine/chemokine agonists of keratinocyte 
proliferation and migration 
Epidermal keratinocyte functions, including migratory and proliferative responses, are well-
established to be regulated by various cytokines and chemokines [25].  However, both epoxy-
tiglianes significantly down-regulated the expression of cytokines, including interleukin (IL)-
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1α, IL-6, IL-8 and tumour necrosis factor-α (TNF-α); and chemokine (C-C motif) ligands, 
(CCL)2, CCL5 and chemokine (C-X-C motif) ligands, (CXCL)1 and CXCL10 [21] (GEO 
database, GSE122297).  Epoxy-tigliane down-regulation of selected cytokines and chemokines 
were verified by ELISA.  Although EBC-46 induced no significant changes in IL-6 levels at 24 
h (p>0.05, Fig. 7A), 1.51 nM-15.1 µM EBC-46 significantly decreased IL-6 levels at 48 h 
(p<0.001-0.01).  Despite a significant increase in IL-6 levels with 15.1 µM EBC-211 at 24 h 
(p<0.05, Fig. 7A), significant decreased IL-6 levels were also evident with 1.51 nM-15.1 µM 
EBC-211 versus untreated controls at 48 h (p<0.001).  Although IL-8 levels were significantly 
increased by 15.1 nM-15.1 µM EBC-46 (p<0.001-0.01) and 151 nM-15.1 µM EBC-211 
(p<0.001-0.05) at 24 h (Fig. 7B), significant decreases in IL-8 levels were detected with 1.51 
nM and 15.1 µM EBC-46 (p<0.01-0.05) and 1.51 nM-15.1 µM EBC-211 (p<0.001-0.05) at 48 
h.  EBC-46 and EBC-211 (1.51 nM-15.1 µM) were further demonstrated to significantly 
decrease CCL5 levels versus untreated controls (Fig. 7C), both at 24 h (p<0.001-0.01 for EBC-
46, p<0.001 for EBC-211) and 48 h (p<0.001 for both EBC-46 and EBC-211).  Similar profiles 
were apparent with CXCL10 (Fig. 7D), with significant reductions in CXCL10 levels with 1.51 
nM-15.1 µM EBC-46 and EBC-211 at 24 h (p<0.001-0.01 for EBC-46; p<0.001 for EBC-211) 
and 48 h (p<0.001 for both EBC-46 and EBC-211). 
 
3.10. Epoxy-tiglianes promote keratinocyte proliferation and migration via PKC activation 
The predominant down-regulation of such cytokines and chemokines implied that epoxy-
tigliane stimulation of HaCaT proliferation and migration were not facilitated via such 
autocrine mechanisms.  As previous work identified that the anti-cancer effects of EBC-46 are 
induced by PKC activation [1], we next established whether PKC activation was also 
responsible for the changes identified above, leading to enhanced HaCaT proliferative and 
migratory responses.  Studies assessed whether the stimulatory effects of EBC-46 and EBC-
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211 on HaCaT proliferation and scratch wound repopulation were abrogated by the 
pharmacological inhibition of PKC activation by pan-PKC inhibitor, BIM-1.  Although both 
epoxy-tiglianes induced significant HaCaT proliferation at 1.51 nM, 151 nM and 15.1 µM 
concentrations versus untreated controls, in line with previous findings, these responses were 
significantly abrogated by BIM-1 at 24 h, 48 h and 72 h post-treatment (p<0.001, Fig. 8A & 
B).  The significantly enhanced scratch wound closure induced by EBC-46 versus untreated 
controls, were also significantly inhibited by BIM-1 at 24 h (1.51 nM, p<0.001) and 48 h (151 
nM and 15.1 µM, p<0.001, Fig. 8C & D and Supplementary Videos, [21]).  Similarly, BIM-1 
significantly inhibited wound closure induced by EBC-211 at 24 h (1.51 nM and 15.1 µM, 
p<0.001) and 48 h (1.51 nM-15.1 µM, p<0.001, Fig. 8E & F and Supplementary Videos, [21]). 
 
3.11. Epoxy-tiglianes modulate keratin, cell cycle-related protein and matrix metalloproteinase 
levels via PKC activation 
We next evaluated BIM-1 effects on the differential expression of selected KRT, cell cycle and 
MMP proteins, following treatment with EBC-46 and EBC-211.  BIM-1 treatment significantly 
increased KRT17 protein levels induced by 15.1 µM EBC-46 (p<0.01) and 151 nM EBC-211 
(p<0.05), at 24 h (Fig. 9A).  BIM-1 had no significant effects on the EBC-46 induced protein 
levels of cyclin B1 (p>0.05, [21]).  However, a significant increase in cyclin B1 levels was 
evident after 48 h treatment with 15.1 µM EBC-211 (p<0.01, Fig. 9B).  BIM-1 was further 
demonstrated to abrogate the epoxy-tigliane-induced down-regulation of CDKN1A, with 
significant increases in CDKN1A detection following 15.1 µM EBC-46 treatment at 24 h 
(p<0.01, Fig. 9C) and 151 nM EBC-46 at 48 h (p<0.05); in addition to significant CDKN1A 
increases with 1.51 nM EBC-211 at 48 h (p<0.05, Fig. 9D).  Furthermore, BIM-1 significantly 
inhibited epoxy-tigliane-induced increases in the activities of MMP-1 (1.51 nM-15.1 µM, 
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p<0.001, Fig. 9E), MMP-7 (1.51 nM and 151 nM EBC-46; 1.51 nM-15.1 µM EBC-211, 
p<0.001-0.05, Fig. 9F); and MMP-10 (1.51 nM-15.1 µM, p<0.001, Fig. 9G), at 48 h. 
 Western blot detection of pan-PKC phosphorylation and activation further showed that 
compared to untreated controls (Fig. 10A), EBC-46 induced PKC phosphorylation, with a dose-
dependent response evident at 1 h, with the greatest increase in phosphorylation induced at 15.1 
µM.  Following 3 h treatment, 151 nM EBC-46 showed the greatest induction of PKC 
phosphorylation.  The dose-dependent induction was again evident at 6 h and 24 h, with 15.1 
µM EBC-46 showing the greatest response.  EBC-211 also promoted rapid phosphorylation at 
15.1 µM at 30 min and 1 h (Fig. 10B).  Following a decline in PKC phosphorylation at 3 h, 
induction was evident at 6 h with 1.51 nM and 151 nM EBC-211, although PKC 
phosphorylation returned to baseline levels at 24 h. 
 
4. Discussion 
This study provides previously unreported insights into how novel epoxy-tiglianes promote 
keratinocyte wound healing responses, in line with the accelerated re-epithelialization and 
wound closure in vivo, post-tumor destruction [1-3].  Epithelial integrity is maintained by 
keratinocytes that switch from basal proliferative states to differentiated states, upon migration 
through the epidermis [5].  In acute healing skin wounds, disassembled cell-cell and cell-matrix 
interactions initiate keratinocyte migration from the wound edge across denuded areas, whereas 
keratinocytes behind the migrating front proliferate.  However, during non-healing chronic skin 
wounds, mitotically active keratinocytes are localized within the supra-basal layers of the 
epithelium due to c-myc activation and overexpression, which impairs healing [7].  
Furthermore, as the epidermal margins of chronic wounds are highly proliferative, 
keratinocytes exhibit a non-migratory phenotype, partly through the failed disruption of cell-
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cell and cell-matrix interactions [9-11].  Consequently, these events attenuate re-
epithelialization and the re-establishment of barrier function. 
This study demonstrated that both EBC-46 and EBC-211 induced significant HaCaT 
proliferation, with concomitant accelerated cell cycle transitions between G1/S and S/G2 
phases.  Coupled with stimulated proliferation were the abilities of EBC-46 and EBC-211 to 
enhance HaCaT migratory and wound repopulation responses, even with MC-inhibited 
proliferation, suggesting that epoxy-tiglianes can promote keratinocyte migration and wound 
repopulation independently of proliferation.  Based on these findings, epoxy-tiglianes appear 
to promote keratinocyte hyper-proliferation.  However, as epoxy-tiglianes also enhanced 
keratinocyte migration and wound repopulation over equivalent time frames, this implies that 
epoxy-tigliane hyper-proliferative responses are shorter than the prolonged hyper-proliferation 
associated with chronic wounds.  Furthermore, increased bursts of proliferative activity were 
evident behind wound edge keratinocytes in repopulation time-lapse videos following epoxy-
tigliane treatment, akin to proliferative bursts occurring behind migrating keratinocytes in acute 
wound margins [26].  Therefore, similar events may be induced by epoxy-tiglianes in vivo 
permitting re-epithelialization, with keratinocyte differentiation presumably resumed upon 
epidermal barrier restoration [27].  Indeed, accelerated keratinocyte proliferative/migratory 
responses and rapid re-epithelialization are hallmarks of highly regenerative tissues, such as 
early-gestational fetal skin and oral mucosa [28,29]. 
 Expression profiling and validation analyses demonstrated that EBC-46 and EBC-211 
collectively induce gene expression changes driving DNA synthesis/replication, cell cycle 
progression, proliferation and migration to facilitate enhanced wound re-epithelialization; at the 
expense of genes associated with apoptosis and keratinocyte differentiation.  Of these, the KRTs 
were particularly prominent, given the pivotal roles of keratin heterodimers and intermediate 
filaments in regulating keratinocyte functions and epithelial integrity [22].  Up-regulated 
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KRT13 and KRT15 were particularly interesting, as these are not typically found in adult skin 
epithelia but are common in supra-basal layers of non-keratinized, oral mucosal and fetal 
epithelia respectively, where these promote rapid re-epithelialization [29,30].  KRT13 up-
regulation is also associated with alternative differentiation and the re-induction of embryonic 
epidermal regeneration [31].  KRT15 is present in epidermal stem cells and basal keratinocytes 
of stratified epithelia, where it stimulates keratinocyte proliferation, although its expression 
declines during terminal differentiation [32]. 
Although KRT6B, KRT16 and KRT17 are common in stratified epithelia and absent in 
uninjured tissue, their down-regulation was unexpected considering the extent of HaCaT 
proliferation and migration induced by epoxy-tiglianes.  Type I/II intermediate filament 
partners, KRT6, KRT16 and KRT17, are markers of decreased desmosome adhesion, increased 
contractility and activated hyper-proliferative/migratory responses in wound edge keratinocytes 
during re-epithelialization [25,33].  However, KRT16 protein is restricted to post-mitotic 
keratinocytes, whilst over-expression inhibits keratinocyte proliferation, migration and re-
epithelialization [34].  Down-regulation of KRT6 and its heterodimer, KRT16, also enhances 
keratinocyte migration and re-epithelialization [35,36]; although KRT17 down-regulation 
inhibits these responses [37].  Therefore, despite our findings being partly counterintuitive to 
the roles these KRTs play post-injury, such studies collectively support the epoxy-tigliane 
manipulation of KRT expression to promote keratinocyte proliferation and migration. 
 In addition to KRTs, epoxy-tiglianes particularly influenced the expression of a 
multitude of genes to promote HaCaT proliferation.  In line with epoxy-tiglianes stimulating 
G0/G1-S and S-G2/M transitions, these included up-regulated cyclins A2, B1 and B2 which 
promote G2/M transition, while cyclin A2 also controls G1-S transition [38].  Concomitant with 
cyclin up-regulation were the differentially regulated cyclin-dependent inhibitors, CDKN3 and 
CDKN1A.  Up-regulated CDKN3 regulates normal mitosis and G1-S transition by arresting G1 
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phase [39], whilst down-regulated CDKN1A attenuates cyclin complex formation with cyclin-
dependent protein kinases, inhibiting G1-S transition [40].  Other up-regulated genes with 
prominent roles in positively mediating various aspects of DNA synthesis/replication, cell cycle 
transition, mitosis, cytokinesis and proliferation, included mini-chromosome maintenance 
proteins, aurora kinases, cell division cycle and centromere proteins, kinesins, GINS2 and 
UBE2C (GEO database, GSE122297) [21,41-46].  In contrast, pro-apoptosis-related genes, 
such as caspases and TNF superfamily members, were down-regulated by epoxy-tiglianes 
[21,47,48]. 
Differential S100 protein expression by epoxy-tiglianes would further influence 
proliferation and migration, as up-regulated S100A4 enhances cell cycle transition, 
keratinocyte hyper-proliferation and motility [23,24].  In contrast, down-regulated S100A7, 
S100A8 and S100A9 would attenuate keratinocyte differentiation and promote 
proliferation/migration [49,50].  The significantly enhanced HaCaT migratory responses 
induced by epoxy-tiglianes would further potentially be stimulated through AGR2 up-
regulation [21,51], although other pro-migratory mediators, such as LCN2, were down-
regulated [21,52].  In further support of augmented HaCaT proliferative and migratory 
responses, as opposed to differentiation, numerous established keratinocyte differentiation 
markers were down-regulated by epoxy-tiglianes, including ANGPTL4, CLCA2, FABP5, 
LAMP3 and RARRES3 (GEO database, GSE122297) [21,53-57]. 
To facilitate keratinocyte migration across underlying matrix during re-
epithelialization, keratinocytes disassemble cell-cell and cell-ECM interactions.  Epoxy-
tiglianes up-regulated MMP-1, MMP-7 and MMP-10, with no effects on MMP inhibitors, 
potentially enhancing keratinocyte migration and re-epithelialization via the degradation of 
basement membranes and underlying dermal matrices [58-60].  Despite enhanced HaCaT 
proliferative and migratory responses by epoxy-tiglianes, many serine proteases and their 
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inhibitors commonly associated with hyper-proliferative keratinocytes, such as PLAU, PI3 and 
SERPINs; were down-regulated by epoxy-tiglianes (GEO database, GSE122297) [21,61-66]. 
Numerous cytokines and chemokines play critical roles in activating keratinocyte 
proliferation and migration during re-epithelialization [25].  However, many cytokine and 
chemokine agonists of keratinocyte proliferation and migration were down-regulated by epoxy-
tiglianes, possibly as a consequence of altered KRT expression [36], implying that these do not 
mediate stimulated keratinocyte responses.  Previous studies have identified that epoxy-
tiglianes possess potent PKC activation capabilities, particularly the classical PKC isoforms (α, 
βI, βII and γ) [1].  PKCs are serine/threonine kinases ascribed numerous roles in regulating 
keratinocyte functions, with the calcium-/diacylglycerol-dependent, classical PKCs having 
opposing proliferative, migratory and differentiation effects [67].  In agreement, both epoxy-
tiglianes induced PKC activation, with selected differentially expressed genes and stimulated 
keratinocyte proliferative/migratory responses identified to be PKC-dependent.  However, 
although epoxy-tigliane bioactivities showed similar gene expression profiles and wound 
healing responses, differences in PKC activation potency were identified.  Such subtle 
differences in PKC phosphorylation, keratinocyte gene expression and responsiveness between 
epoxy-tigliane analogues and concentrations, are likely consequences of differences in PKC 
isoform expression, distribution, translocation and activity, potentially leading to dose-
independent or biphasic effects on cellular activities; as established with other PKC activators 
[67].  Indeed, short-term exposure or low PKC activator concentrations are recognized to 
promote rapid PKC intracellular translocation and activation, whereas further exposure or 
higher activator concentrations induce catalytic PKC domain release from the inhibitory PKC 
pseudo-substrate domain, resulting in constitutive activation.  Although prolonged exposure 
can down-regulate PKC activity via catalytic PKC domain proteolysis, PKCα is resistant to 
such degradation during sustained stimulation [68].  Therefore, the prolonged PKC 
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phosphorylation and activation induced by epoxy-tiglianes, particularly at higher 
concentrations, appear responsible for changes in the expression of downstream targets, such 
as KRTs, cyclins and MMPs; leading to enhanced keratinocyte wound healing responses. 
PKCα is the most abundant isoform in the epidermis, localised to supra-basal layers.  
PKCα is anti-proliferative and stimulatory to keratinocyte differentiation/wound re-
epithelialization.  In contrast, PKCγ is undetectable in keratinocytes [69], whilst PKCβ 
promotes keratinocyte proliferation and inhibits differentiation [70,71]; although both PKCα 
and PKCβII facilitate keratinocyte motility [11,72].  This suggests that epoxy-tigliane 
enhancement of keratinocyte proliferation, migration and re-epithelialization are principally 
mediated by PKCα and PKCβ isoforms.  Unlike acute healing wounds, PKCα activation and 
keratinocyte migration are impaired in non-healing, chronic wounds [11].  However, as type 
I/II intermediate filament partners, KRT6 and KRT17, promote PKCα activation and 
keratinocyte migration [33]; KRT6 and KRT17 down-regulation by epoxy-tiglianes implies 
that enhanced keratinocyte migration occurs via alternative mechanisms.  Consequently, 
although we anticipate that both PKCα and PKCβ are key contributors to enhanced keratinocyte 
proliferation and migration by epoxy-tiglianes, further studies will delineate the precise 
involvement of specific PKC isoforms in regulating epoxy-tigliane wound healing responses 
and other downstream cell signalling pathways involved in mediating these responses.  
Furthermore, as EBC-46 and EBC-211 comprise some of the >20 different natural and semi-
synthetic epoxy-tigliane analogues now available, we are also investigating their structure-
functional relationships amongst this broader group of compounds relevant to PKC activity, 
keratinocyte wound healing responses and re-epithelialization, with the ultimate objective of 
selecting lead candidate(s) for future development as wound healing pharmaceuticals. 
In summary, this study has demonstrated that epoxy-tigliane activation of PKCs induces 
the multi-faceted modulation of keratinocyte gene expression, which collectively drives the 
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stimulation of proliferation and migratory responses; thereby explaining the enhanced wound 
re-epithelialization observed in epoxy-tigliane-treated skin, post-tumor destruction.  As existing 
therapies are generally inadequate, such findings highlight the potential and further 
development of epoxy-tiglianes as a novel class of topical therapeutics for other clinical 
situations associated with impaired re-epithelialization, such as non-healing skin wounds. 
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Fig. 1.  (A) Chemical structures of epoxy-tiglianes, EBC-46 (tiglianol tiglate) and EBC-46 
analogue, EBC-211 (produced by a Payne re-arrangement of the epoxide group on the β ring of 
EBC-46, circled in red).  Stimulatory effects of epoxy-tiglianes on human skin keratinocyte 
(HaCaT) proliferation and cell cycle progression.  (B-C) MTT analysis of HaCaT proliferation 
and viability, following treatment with 1.51 nM-151 µM EBC-46 and EBC-211 over 168 h, 
versus untreated HaCaTs.  (D-E) DRAQ5™ and flow cytometry analysis of cell cycle 
progression and corresponding histogram depictions of % cells in each cell cycle phase, 
following HaCaT treatment with 1.51 nM-15.1 µM EBC-46 and EBC-211 for 40 h, versus 
untreated HaCaTs.  See Supplementary Data from other cell cycle time-points analyzed, [21].  
Results are presented as mean ± SEM, n=3 independent experiments.  Significance at *p<0.05, 
**p<0.01 and ***p<0.001, versus untreated controls. 
Fig. 2.  Epoxy-tigliane enhancement of human skin keratinocyte (HaCaT) migration and scratch 
wound repopulation.  (A) Representative Time-Lapse Microscopy images of HaCaT scratch 
wound repopulation at 48 h, following treatment with 1.51 nM-15.1 µM EBC-46 versus 
untreated HaCaTs (see Supplementary Videos S1 and S2 online for untreated and 1.51 nM 
EBC-46 scratch wounds over 48 h; and Supplementary Videos for 15.1 nM-15.1 µM EBC-46 
treated HaCaTs, [21]).  (B) ImageJ® analysis of HaCaT scratch wound repopulation and closure 
rates at 24 h and 48 h, following treatment with 1.51 nM-15.1 µM EBC-46 versus untreated 
HaCaTs.  (C) Representative Time-Lapse Microscopy images of HaCaT scratch wound 
repopulation at 48 h, following treatment with 1.51 nM-15.1 µM EBC-211 versus untreated 
HaCaTs (see Supplementary Videos S3 and S4 online for untreated and 1.51 nM EBC-211 
scratch wounds over 48 h; and Supplementary Videos for 15.1 nM-15.1 µM EBC-211 treated 
HaCaTs, [21]).  (D) ImageJ® analysis of HaCaT scratch wound repopulation and closure rates 
at 24 h and 48 h, following treatment with 1.51 nM-15.1 µM EBC-211 versus untreated 
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HaCaTs.  Results are presented as mean ± SEM, n=3 independent experiments.  Significance 
at *p<0.05, **p<0.01 and ***p<0.001, versus untreated controls.  White dashed lines show 
original scratch wound distances at 0 h.  Scale bar = 100 μm. 
Fig. 3.  Epoxy-tigliane enhancement of human skin keratinocyte (HaCaT) migration and scratch 
wound repopulation, independently of increased proliferation.  (A-B) ImageJ® analysis of 
HaCaT scratch wound repopulation and closure rates at 24 h and 48 h, following treatment with 
EBC-46 or EBC-211 (1.51 nM-15.1 µM) versus untreated HaCaTs, ± MC (see Supplementary 
Videos for untreated and 1.51 nM-15.1 µM EBC-46 and EBC-211 treated HaCaTs, [21]).  
Results are presented as mean ± SEM, n=3 independent experiments.  Significance at *p<0.05, 
**p<0.01 and ***p<0.001, versus untreated controls. 
Fig. 4.  Epoxy-tiglianes modulate human skin keratinocyte (HaCaT) keratin gene and protein 
expression profiles to stimulate enhanced proliferation and migration.  (A) Transcriptomic 
analysis by Illumina BeadChip Microarrays and heatmap visualization of genes differentially 
xpressed 2-fold by HaCaTs, following treatment with 1.51 nM, 151 nM or 15.1 µM EBC-46 
or EBC-211 for 24 h and 48 h, versus untreated HaCaTs (based on n=4 independent profiling 
experiments for EBC-46 and EBC-211).  (B) Western blot images and ImageJ® densitometric 
analysis of KRT13 protein levels, following HaCaT treatment with 1.51 nM-15.1 µM EBC-211 
for 48 h, versus untreated HaCaTs.  (C) Western blot images and ImageJ® densitometric 
analysis of KRT15 protein levels, following HaCaT treatment with 1.51 nM-15.1 µM EBC-211 
for 24 h, versus untreated HaCaTs.  For all Western blots, images from one representative 
experiment of three are shown.  Results are presented as mean ± SEM, n=3 independent 
experiments.  Significance at *p<0.05 versus untreated controls. 
Fig. 5.  Epoxy-tiglianes modulate human skin keratinocyte (HaCaT) cell cycle/proliferation-
associated protein expression profiles to stimulate enhanced proliferation and migration.  (A) 
Western blot images and ImageJ® densitometric analysis of cyclin A2 protein levels, following 
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HaCaT treatment with 1.51 nM-15.1 µM EBC-46 for 48 h, versus untreated HaCaTs.  (B) 
Western blot images and ImageJ® densitometric analysis of cyclin B1 protein levels, following 
HaCaT treatment with 1.51 nM-15.1 µM EBC-46 for 24 h, versus untreated HaCaTs.  (C) 
Western blot images and ImageJ® densitometric analysis of cyclin B2 protein levels, following 
HaCaT treatment with 1.51 nM-15.1 µM EBC-46 for 24 h and 48 h, versus untreated HaCaTs.  
(D) Western blot images and ImageJ® densitometric analysis of cyclin B2 protein levels, 
following HaCaT treatment with 1.51 nM-15.1 µM EBC-211 for 48 h, versus untreated 
HaCaTs.  (E) Western blot images and ImageJ® densitometric analysis of CDKN1A protein 
levels, following HaCaT treatment with 1.51 nM-15.1 µM EBC-46 or EBC-211 for 24 h, versus 
untreated HaCaTs.  For all Western blots, images from one representative experiment of three 
are shown.  Results are presented as mean ± SEM, n=3 independent experiments.  Significance 
at *p<0.05, **p<0.01 and ***p<0.001, versus untreated controls. 
Fig. 6.  Epoxy-tiglianes regulate MMP and S100 protein expression profiles in human skin 
keratinocytes (HaCaTs) to stimulate enhanced proliferation and migration.  (A-C) MMP-1, 
MMP-7 and MMP-10 activities (activity assays), following HaCaT treatment with 1.51 nM-
15.1 µM EBC-46 or EBC-211 for 24 h and 48 h, versus untreated HaCaTs.  (D) Western blot 
images and ImageJ® densitometric analysis of S100A4 protein levels, following HaCaT 
treatment with 1.51 nM-15.1 µM EBC-46 for 24 h, versus untreated HaCaTs.  (E) Western blot 
images and ImageJ® densitometric analysis of S100A8 protein levels, following HaCaT 
treatment with 1.51 nM-15.1 µM EBC-46 or EBC-211 for 48 h, versus untreated HaCaTs.  For 
all Western blots, images from one representative experiment of three are shown.  Results are 
presented as mean ± SEM, n=3 independent experiments.  Significance at *p<0.05, **p<0.01 
and ***p<0.001, versus untreated controls. 
Fig. 7.  Epoxy-tiglianes inhibit the expression and protein levels of key cytokine and chemokine 
agonists of human skin keratinocyte (HaCaT) proliferation and migration.  (A-B) ELISA 
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analysis of selected cytokine (IL-6, IL-8) levels, following HaCaT treatment with 1.51 nM-15.1 
µM EBC-46 or EBC-211 for 24 h and 48 h, versus untreated HaCaTs.  (C-D) ELISA analysis 
of selected chemokine (CCL5, CXCL10) levels, following HaCaT treatment with 1.51 nM-15.1 
µM EBC-46 or EBC-211 for 24 h and 48 h, versus untreated HaCaTs.  Results are presented as 
mean ± SEM, n=3 independent experiments.  Significance at *p<0.05, **p<0.01 and 
***p<0.001, versus untreated controls. 
Fig. 8.  PKC activation mediates enhanced human skin keratinocyte (HaCaT) proliferative and 
migratory responses by epoxy-tiglianes.  (A-B) MTT analysis of proliferation, following 
HaCaT treatment with 1.51 nM, 151 nM or 15.1 µM EBC-46 or EBC-211, over 72 h versus 
untreated HaCaTs, ± pan-PKC inhibitor, BIM-1 (1 µM).  (C-D) Representative Time-Lapse 
Microscopy images and ImageJ® analysis of HaCaT scratch wound repopulation at 24h and 48 
h, following treatment with 1.51 nM, 151 nM or 15.1 µM EBC-46, versus untreated HaCaTs 
over 48 h, ± BIM-1 (see Supplementary Videos for untreated and EBC-46-treated HaCaTs, 
[21]).  (E-F) Representative Time-Lapse Microscopy images and ImageJ® analysis of HaCaT 
scratch wound repopulation at 24h and 48 h, following treatment with 1.51 nM, 151 nM or 15.1 
µM EBC-211, versus untreated HaCaTs over 48 h, ± BIM-1 (see Supplementary Videos for 
untreated and EBC-211-treated HaCaTs, [21]).  Results are presented as mean ± SEM, n=3 
independent experiments.  Significance at *p<0.05 and ***p<0.001, versus corresponding 
BIM-1-free controls.  White dashed lines show original scratch wound distances at 0 h.  Scale 
bar = 100 μm. 
Fig. 9.  PKC activation modulates keratin, cell cycle and MMP gene expression profiles by 
epoxy-tiglianes to enhance human skin keratinocyte (HaCaT) proliferation and migration.  (A) 
Western blot images and ImageJ® densitometric analysis of KRT17 protein levels, following 
HaCaT treatment with 1.51 nM, 151 nM or 15.1 µM EBC-46 or EBC-211 for 24 h, versus 
untreated HaCaTs, ± pan-PKC inhibitor, BIM-1 (1 µM).  (B) Western blot images and ImageJ® 
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densitometric analysis of cyclin B1 protein levels, following HaCaT treatment with 1.51 nM, 
151 nM or 15.1 µM EBC-211 for 48 h, versus untreated HaCaTs, ± pan-PKC inhibitor, BIM-
1.  (C) Western blot images and ImageJ® densitometric analysis of CDKN1A protein levels, 
following HaCaT treatment with 1.51 nM, 151 nM or 15.1 µM EBC-46 for 24 h and 48 h, 
versus untreated HaCaTs, ± pan-PKC inhibitor, BIM-1.  (D) Western blot images and ImageJ® 
densitometric analysis of CDKN1A protein levels, following HaCaT treatment with 1.51 nM, 
151 nM or 15.1 µM EBC-211 for 48 h, versus untreated HaCaTs, ± pan-PKC inhibitor, BIM-
1.  (E-G) MMP-1, MMP-7 and MMP-10 activities (activity assays), following HaCaT treatment 
with 1.51 nM, 151 nM or 15.1 µM EBC-46 or EBC-211 for 48 h, versus untreated HaCaTs, ± 
BIM-1.  For all Western blots, images from one representative experiment of three are shown.  
Results are presented as mean ± SEM, n=3 independent experiments.  Significance at *p<0.05, 
**p<0.01 and ***p<0.001, versus corresponding BIM-1-free controls. 
Fig. 10.  PKC phosphorylation and activation profiles induced by epoxy-tiglianes to enhance 
human skin keratinocyte (HaCaT) proliferation and migration.  (A-B) Western blot images and 
ImageJ® densitometric analysis of pan-PKC phosphorylation, following HaCaT treatment with 
1.51 nM, 151 nM or 15.1 µM EBC-46 or EBC-211 over 24 h, versus untreated HaCaTs.  For 
all Western blots, images from one representative experiment of three are shown.  Results are 
presented as mean ± SEM, n=3 independent experiments. 
Fig. 1A







Fig. 3A Fig. 3B
Fig. 4A















Fig. 8A Fig. 8B
Fig. 8C Fig. 8D
Fig. 8E Fig. 8F
Fig. 9A
Fig. 9B
Fig. 9C
Fig. 9D
Fig. 9E
Fig. 9F
Fig. 9G
Fig. 10A
Fig. 10B
